[Protective effects of ranitidine in ibuprofen gastroduodenopathy. An endoscopic controlled double blind study].
Protective Effect of Ranitidine in Ibuprofen Gastroduodenopathy/An endoscopically controlled double-blind study in healthy volunteers. In a randomized parallel double-blind study the gastroduodenal effects of 600 mg ibuprofen racemate (CAS 15687-27-1) tid in the presence of 150 mg ranitidine (CAS 66357-35-5, Sostril) bid or placebo was evaluated in 32 healthy volunteers undergoing upper gastrointestinal endoscopy. Drugs were taken during a period of 7 days. Endoscopic controls were performed at entry and repeated after 7 days of treatment. A damaging score was used to asses the lesions. At entry both groups showed comparable mucosal damages. The median values under ibuprofen/placebo were 1 (range 0-1) and under ibuprofen/ranitidine 1 (range 0-2). After 7 days of treatment the median lesions score increased under ibuprofen/placebo to 8 (range 1-20) whereas corresponding values in the ibuprofen/ranitidine group were constant at 1 (range 1-9). The differences between both groups were statistically significant (p < 0.05). Our data underline the protective effect of ranitidine 150 mg bid against ibuprofen both on the stomach as well as on the duodenum.
Müller
P
P
Krankenhaus Salem, Heidelberg.
Koch
E M
EM
Simon
B
B
D000293:Adolescent; D000328:Adult; D004311:Double-Blind Method; D016099:Endoscopy, Gastrointestinal; D006801:Humans; D007052:Ibuprofen / Q000037:antagonists & inhibitors* / Q000633:toxicity; D008297:Male; D010437:Peptic Ulcer / Q000139:chemically induced / Q000517:prevention & control*; D011899:Ranitidine / Q000627:therapeutic use*
D011899:Ranitidine; D007052:Ibuprofen